VTVT vs. CRDF, ALMS, OGI, LFCR, CGEN, LRMR, AMRN, CTNM, VIRI, and ZYBT
Should you be buying vTv Therapeutics stock or one of its competitors? The main competitors of vTv Therapeutics include Cardiff Oncology (CRDF), Alumis (ALMS), Organigram (OGI), Lifecore Biomedical (LFCR), Compugen (CGEN), Larimar Therapeutics (LRMR), Amarin (AMRN), Contineum Therapeutics (CTNM), Virios Therapeutics (VIRI), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry.
vTv Therapeutics vs.
vTv Therapeutics (NASDAQ:VTVT) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, community ranking, valuation and earnings.
vTv Therapeutics received 311 more outperform votes than Cardiff Oncology when rated by MarketBeat users. However, 64.06% of users gave Cardiff Oncology an outperform vote while only 57.61% of users gave vTv Therapeutics an outperform vote.
vTv Therapeutics has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500.
In the previous week, Cardiff Oncology had 6 more articles in the media than vTv Therapeutics. MarketBeat recorded 7 mentions for Cardiff Oncology and 1 mentions for vTv Therapeutics. Cardiff Oncology's average media sentiment score of 0.93 beat vTv Therapeutics' score of 0.00 indicating that Cardiff Oncology is being referred to more favorably in the news media.
vTv Therapeutics presently has a consensus target price of $35.00, indicating a potential upside of 73.27%. Cardiff Oncology has a consensus target price of $10.33, indicating a potential upside of 117.54%. Given Cardiff Oncology's higher possible upside, analysts clearly believe Cardiff Oncology is more favorable than vTv Therapeutics.
vTv Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -6,238.17%. Cardiff Oncology's return on equity of -73.97% beat vTv Therapeutics' return on equity.
17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 1.3% of vTv Therapeutics shares are owned by insiders. Comparatively, 7.8% of Cardiff Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
vTv Therapeutics has higher revenue and earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than vTv Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Cardiff Oncology beats vTv Therapeutics on 10 of the 17 factors compared between the two stocks.
Get vTv Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
vTv Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VTVT) was last updated on 2/22/2025 by MarketBeat.com Staff
